CAS Number51481-61-9
Synonyms1-Cyano-2-methyl-3-(2-{[(4-methyl-1H-imidazol-5-yl)methyl]sulfanyl}ethyl)guanidine; Acinil; EINECS 257-232-2; Cimetidine; ULCIMET; 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine; 1-Cyano-3-methyl-2-(2-{[(4-methyl-1H-imidazol-5-yl)methyl]sulfanyl}ethyl)guanidine; Cimal; N-Cyano-N'-methyl-N''-[2-[[(4-methyl-1H-imidazol-5-yl)methyl]thio]ethyl]guanidine; Dyspamet; Brumetadina; MFCD00133296; Tagamet
Molecular FormulaC10H16N6S
Molecular Weight252.34
Purity98%
Density1.3±0.1 g/cm3
Boiling Point476.2±55.0 °C at 760 mmHg
Melting Point139-144°C
Appearancepowder
EINECS257-232-2
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 51481-61-9 |
| Catalog No. | 2A-9009795 |
| Chinese Name | 西咪替丁 |
| Synonyms | 1-Cyano-2-methyl-3-(2-{[(4-methyl-1H-imidazol-5-yl)methyl]sulfanyl}ethyl)guanidine; Acinil; EINECS 257-232-2; Cimetidine; ULCIMET; 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine; 1-Cyano-3-methyl-2-(2-{[(4-methyl-1H-imidazol-5-yl)methyl]sulfanyl}ethyl)guanidine; Cimal; N-Cyano-N'-methyl-N''-[2-[[(4-methyl-1H-imidazol-5-yl)methyl]thio]ethyl]guanidine; Dyspamet; Brumetadina; MFCD00133296; Tagamet |
| Molecular Formula | C10H16N6S |
| Molecular Weight | 252.34 |
| Purity | 98 |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 476.2±55.0 °C at 760 mmHg |
| Melting Point | 139-144°C |
| Appearance | powder |
| Water Solubility | 0.5 g/100 mL at 20 ºC |
| Storage Condition | Sealed, stored at 2ºC -8ºC |
| Application | Cimetidine is an H2 receptor antagonist. |
| EINECS | 257-232-2 |
| HTC | 2933990090 |
| PubChem ID | 24277766 |
| MDL Number | MFCD00133296 |
| SMILES | CN\C(NC#N)=N\CCSCc1nc[nH]c1C |
| InChI | 1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14) |
| InChI Key | AQIXAKUUQRKLND-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | Transport |
| MSDS | msds/9795_1_51481_61_9.pdf |
| Bioactivity | Cimetidine is a histamine-2 (H2) receptor antagonist.IC50 Value: Target: Histamine-2 Receptorin vitro: Cimetidine, a partial agonist for H2R, has a pharmacological profile different from ranitidine and famotidine, possibly contributing to its antitumor activity on gastrointestinal cancers [1]. Cimetidine had no effect on the uptake and cytotoxicity of cisplatin in ovarian cancer cells with high OCT2 mRNA levels (IGROV-1 cells) [2]. Cimetidine showed no effect on proliferation, survival, migration and invasion of 3LL cells. Cimetidine reversed MDSC-mediated T-cell suppression, and improved IFN-γ production. [3]. Cimetidine-mediated down-regulation of NCAM involved suppression of the nuclear translocation of NF-kappaB, a transcriptional activator of NCAM gene expression [4].in vivo: the antitumor efficacy of cisplatin in mice bearing luciferase-tagged IGROV-1 xenografts was unaffected by cimetidine (P = 0.39). Data obtained in 18 patients receiving cisplatin (100 mg/m(2)) in a randomized crossover fashion with or without cimetidine (800 mg × 2) revealed that cimetidine did not alter exposure to unbound cisplatin [2]. cimetidine reduced CD11b(+)Gr-1(+) myeloid derived-suppressive cell (MDSC) accumulation in spleen, blood and tumor tissue of tumor-bearing mice [3]. Cimetidine exerts a beneficial effect on periodontal disease in rats, decreasing the RANKL/OPG ratio in gingival connective tissue and reducing alveolar bone resorption [5]. Related Catalog Signaling Pathways >> GPCR/G Protein >> Histamine Receptor Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Research Areas >> Cancer References [1]. Takahashi, H.K., et al., Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol, 2006. 70(2): p. 450-3. [2]. Sprowl, J.A., et al., Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther, 2013. 94(5): p. 585-92. [3]. Zheng, Y., et al., Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol Immunol, 2013. 54(1): p. 74-83. [4]. Fukuda, M., K. Kusama, and H. Sakashita, Cimetidine inhibits salivary gland tumor cell adhesion to neural cells and induces apoptosis by blocking NCAM expression. BMC Cancer, 2008. 8: p. 376. [5]. Longhini, R., et al., Cimetidine Reduces the Alveolar Bone Loss in Induced Periodontitis in Rat Molars. J Periodontol, 2013. Chemical & Physical Properties Density 1.3±0.1 g/cm3 Boiling Point 476.2±55.0 °C at 760 mmHg Melting Point 139-144°C Molecular Formula C10H16N6S Molecular Weight 252.339 Flash Point 241.8±31.5 °C Exact Mass 252.115707 PSA 114.19000 LogP 0.07 Vapour Pressure 0.0±1.2 mmHg at 25°C Index of Refraction 1.632 InChIKey AQIXAKUUQRKLND-UHFFFAOYSA-N SMILES CN=C(NC#N)NCCSCc1nc[nH]c1C Storage condition 2-8°C Water Solubility 0.5 g/100 mL at 20 ºC |
| Use of | Properties Articles101 Name cimetidine Synonym More Synonyms Cimetidine Biological Activity Related Catalog Signaling Pathways >> GPCR/G Protein >> Histamine Receptor Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Research Areas >> Cancer References [1]. Takahashi, H.K., et al., Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol, 2006. 70(2): p. 450-3. [2]. Sprowl, J.A., et al., Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther, 2013. 94(5): p. 585-92. [3]. Zheng, Y., et al., Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol Immunol, 2013. 54(1): p. 74-83. [4]. Fukuda, M., K. Kusama, and H. Sakashita, Cimetidine inhibits salivary gland tumor cell adhesion to neural cells and induces apoptosis by blocking NCAM expression. BMC Cancer, 2008. 8: p. 376. [5]. Longhini, R., et al., Cimetidine Reduces the Alveolar Bone Loss in Induced Periodontitis in Rat Molars. J Periodontol, 2013. Chemical & Physical Properties Molecular Formula C10H16N6S Exact Mass 252.115707 PSA 114.19000 Index of Refraction 1.632 InChIKey AQIXAKUUQRKLND-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 99.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Chlorimipramine Hydrochlorideï¼3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine hydrochloride | 17321-77-6 | 2A-9009734 |
| Chloroquine | 54-05-7 | 2A-9009747 |
| Chloroquine diphosphate | 50-63-5 | 2A-9009748 |
| Chlorotetracycline | 57-62-5 | 2A-9009749 |
| Chlortetracycline hydrochloride | 64-72-2 | 2A-9009761 |
| Cimetidine hydrochloride | 70059-30-2 | 2A-9009796 |
| Ciprofloxacin | 85721-33-1 | 2A-9009818 |
| Ciprofloxacin hydrochloride | 86393-32-0 | 2A-9009819 |
| Ciprofloxacin lactate | 97867-33-9 | 2A-9009820 |
| Clarithromycin | 81103-11-9 | 2A-9009826 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS